JP7373904B2 - セブラノパドールの滴定 - Google Patents

セブラノパドールの滴定 Download PDF

Info

Publication number
JP7373904B2
JP7373904B2 JP2018543634A JP2018543634A JP7373904B2 JP 7373904 B2 JP7373904 B2 JP 7373904B2 JP 2018543634 A JP2018543634 A JP 2018543634A JP 2018543634 A JP2018543634 A JP 2018543634A JP 7373904 B2 JP7373904 B2 JP 7373904B2
Authority
JP
Japan
Prior art keywords
cebranopadol
daily dose
days
period
dosing period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507148A (ja
Inventor
ワン・シャオナン
ピアーナ・キアラ
ブルシー・ロベルタ
Original Assignee
パーク・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーク・セラピューティクス・インコーポレイテッド filed Critical パーク・セラピューティクス・インコーポレイテッド
Publication of JP2019507148A publication Critical patent/JP2019507148A/ja
Priority to JP2021111672A priority Critical patent/JP2021169472A/ja
Application granted granted Critical
Publication of JP7373904B2 publication Critical patent/JP7373904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018543634A 2016-02-29 2017-02-28 セブラノパドールの滴定 Active JP7373904B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021111672A JP2021169472A (ja) 2016-02-29 2021-07-05 セブラノパドールの滴定

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16157868.7 2016-02-29
EP16157868 2016-02-29
EP16020302 2016-08-11
EP16020302.2 2016-08-11
PCT/EP2017/025034 WO2017148595A1 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021111672A Division JP2021169472A (ja) 2016-02-29 2021-07-05 セブラノパドールの滴定

Publications (2)

Publication Number Publication Date
JP2019507148A JP2019507148A (ja) 2019-03-14
JP7373904B2 true JP7373904B2 (ja) 2023-11-06

Family

ID=58185482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543634A Active JP7373904B2 (ja) 2016-02-29 2017-02-28 セブラノパドールの滴定
JP2021111672A Pending JP2021169472A (ja) 2016-02-29 2021-07-05 セブラノパドールの滴定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021111672A Pending JP2021169472A (ja) 2016-02-29 2021-07-05 セブラノパドールの滴定

Country Status (10)

Country Link
US (3) US11229625B2 (https=)
EP (1) EP3423054A1 (https=)
JP (2) JP7373904B2 (https=)
CN (2) CN118286209A (https=)
AU (1) AU2017226830B2 (https=)
BR (1) BR112018017167A2 (https=)
CA (1) CA3015420C (https=)
IL (1) IL261133A (https=)
MX (1) MX2018010367A (https=)
WO (1) WO2017148595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339105B1 (en) 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
JP2006513184A (ja) 2002-12-13 2006-04-20 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
JP2006519849A (ja) 2003-03-11 2006-08-31 ユーロ−セルティーク エス．エイ． 放出制御トラマドールの漸増投薬処方
JP2010531296A (ja) 2007-04-23 2010-09-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの用量調節
JP2013532697A (ja) 2010-08-04 2013-08-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 神経因性疼痛の治療のための６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025769A1 (en) * 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DK2600846T3 (en) 2010-08-04 2016-01-11 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-fluoro- (N-methyl or N, N-dimethyl -) - 4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3 , 4, b] indole] -4-amine
RS54438B1 (sr) 2010-08-04 2016-06-30 Grünenthal GmbH Farmaceutski dozni oblik koji sadrži 6`-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-amina
NZ604735A (en) 2010-08-04 2014-08-29 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
PL2649044T3 (pl) 2010-12-08 2018-02-28 Grünenthal GmbH Sposób syntezy podstawionych pochodnych aminocykloheksanonu
CN106939005A (zh) 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
ES2577861T3 (es) 2011-12-12 2016-07-19 Grünenthal GmbH Proceso para la preparación de (1R,4R)-6'-fluor-(N,N-dimetil- y N-metil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina
US8912343B2 (en) 2011-12-12 2014-12-16 Gruenenthal Gmbh Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
MX353331B (es) 2011-12-12 2018-01-09 Gruenenthal Gmbh Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina.
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
HUE040039T2 (hu) 2014-02-27 2019-02-28 Gruenenthal Gmbh Az 5-fluor-triptofol elõállítására szolgáló eljárás
CA2974578C (en) 2015-01-23 2020-11-17 Grunenthal Gmbh Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339105B1 (en) 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
JP2006513184A (ja) 2002-12-13 2006-04-20 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
JP2006519849A (ja) 2003-03-11 2006-08-31 ユーロ−セルティーク エス．エイ． 放出制御トラマドールの漸増投薬処方
JP2010531296A (ja) 2007-04-23 2010-09-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの用量調節
JP2013532697A (ja) 2010-08-04 2013-08-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 神経因性疼痛の治療のための６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＰＨＡＲＭＡＣＯＴＨＥＲＡＰＹ，１９９９年，Ｖｏｌ．１９，Ｎｏ．１，ｐ．８８～９３

Also Published As

Publication number Publication date
MX2018010367A (es) 2018-12-10
JP2021169472A (ja) 2021-10-28
AU2017226830B2 (en) 2021-06-24
CN109069483A (zh) 2018-12-21
CN118286209A (zh) 2024-07-05
IL261133A (en) 2018-10-31
AU2017226830A1 (en) 2018-08-16
CA3015420A1 (en) 2017-09-08
CA3015420C (en) 2023-09-26
US11229625B2 (en) 2022-01-25
US20220110914A1 (en) 2022-04-14
WO2017148595A1 (en) 2017-09-08
US20250255849A1 (en) 2025-08-14
BR112018017167A2 (pt) 2019-01-02
EP3423054A1 (en) 2019-01-09
JP2019507148A (ja) 2019-03-14
US20180369199A1 (en) 2018-12-27
US12161627B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
US11559523B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
US20230263799A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
US20240238276A1 (en) Method of maintaining remission of depressive symptoms
KR102309836B1 (ko) 비만의 치료
JP2021088575A5 (https=)
RU2562571C2 (ru) Педиатрические композиции для лечения рассеянного склероза
JP7373904B2 (ja) セブラノパドールの滴定
CN110662537A (zh) 用于治疗共核蛋白病的组合物和方法
CN110719778A (zh) 用于治疗抑郁的组合物和方法
US20040043990A1 (en) Method of treatment
JP2013537232A5 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220224

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220302

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220325

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220330

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220819

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231024

R150 Certificate of patent or registration of utility model

Ref document number: 7373904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150